Vimarsana
Biggest News Aggregation in the World

Page 10 - Upstream Processing News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Upstream Processing. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Upstream Processing Today - Breaking & Trending Today

New Merck KGgA viral vector CDMO plant opens in California - Vimarsana News

New Merck KGgA viral vector CDMO plant opens in California

Merck KGgA and subsidiary MilliporeSigma have completed work on their second Carlsbad, California-based facility.

Fujifilm Diosynth in tie-up with US AAV gene therapy developer - Vimarsana News

Fujifilm Diosynth in tie-up with US AAV gene therapy developer

LEXEO Therapeutics, a clinical-stage gene therapy company, is partnering with CDMO, Fujifilm Diosynth Biotechnologies (FDB), to support the development and manufacturing of its AAV-mediated gene therapies.

Avid Bioservices expands into manufacturing services for cell and gene therapy - Vimarsana News

Avid Bioservices expands into manufacturing services for cell and gene therapy

Avid Bioservices, Inc. is expanding its CDMO service offering into the cell and gene therapy market: constructing a purpose-built 53,000 sq. ft. viral vector development and CGMP manufacturing facility in Costa Mesa, CA.

Measuring the benefit of coal-to-LNG switching [Gas in Transition] - Vimarsana News

Measuring the benefit of coal-to-LNG switching [Gas in Transition]

Measuring total LNG supply chain methane emissions is imprecise, but there is an even bigger data gap when it comes to coal. Without accurate measurement, the benefits of coal-to-LNG switching risk being under-appreciated. [Gas in Transition, Volume 1, Issue 6]

PTC Therapeutics opens gene therapy manufacturing facility - Vimarsana News

PTC Therapeutics opens gene therapy manufacturing facility

PTC Therapeutics is celebrating the opening of a new gene therapy manufacturing facility in Hopewell, N.J.